Sino Medical Sciences Technology Inc.

Sinomed Cardiovita Technology Inc.

Sinomed Neurovita Technology Inc.

Tianzhu Li

Jianlu Ma

Xiaoran Kang

Jianhua Sun

Wenbin Cai

Yong Huo

Christophe Bureau

Jianxiang Ma

Lei Meng

Jinhong Zhao

Xueying Wang

Zhonghua Li

Zhongrong Miao

Jing Li

The present invention provides a transapical implantable mitral valve device, which includes an outer valve stent comprising an outer valve stent body that is composed of a plurality of first structure units arranged in the circumferential direction and an anchoring unit that is disposed on the outer valve stent body for anchoring the mitral valve device in a human body, at least one of an inner surface and an outer surface of the outer valve stent body being covered with an outer skirt; an inner valve stent disposed inside the outer valve stent and interconnected with the outer valve stent, a cavity being formed between the outer valve stent and the inner valve stent; and a valve leaflet structure disposed in the inner valve stent to form a prosthetic valve.

Transapical implantable mitral valve device

The present application relates to a balloon catheter, which is a rapid exchange structure and has a balloon catheter body and a hub, wherein the balloon catheter body has a push member, a transition member, a balloon loading member, a balloon, a imaging mark and a tip head, the balloon loading member comprises an outer tube and an inner tube, a distal end of the handle is connected with a proximal end of the push member, a proximal end of the transition member extends from a distal end of the push member, a distal end of the transition member is nested inside a proximal end of the outer tube of the balloon loading member, the balloon loading member loads the balloon, the tip head is provided on a distal end of the balloon, the imaging mark is provided on the balloon loading member, characterized in that the balloon has a wall thickness of 10-15 microns, the balloon has a nominal dilation pressure of 3-4 atm, and the balloon catheter has a rated burst pressure of is 10-12 atm.

Balloon catheter

The present disclosure relates to drug eluting stents, methods of making, using, and verifying long-term stability of the drug eluting stents, and methods for predicting long term stent efficacy and patient safety after implantation of a drug eluting stent. In one embodiment, a drug eluting stent may include a stent framework; a drug-containing layer; a drug embedded in the drug-containing layer; and a biocompatible base layer disposed over the stent framework and supporting the drug-containing layer. The drug-containing layer may have an uneven coating thickness. In addition or in alternative, the drug-containing layer may be configured to significantly dissolve/dissipate/disappear between 45 days and 60 days after stent implantation. Stents of the present disclosure may reduce, minimize, or eliminate patient risks associated with the implantation of a stent, including, for example, restenosis, thrombosis, and/or MACE.

Drug eluting stent and method of use of the same for enabling restoration of functional endothelial cell layers

A mitral valve replacement device is adapted to be deployed at a mitral valve position in a human heart. The device has an atrial flange defining an atrial end of the device, a ventricular portion defining a ventricular end of the device, the ventricular portion having a height ranging between 2 mm to 15 mm, and an annulus support that is positioned between the atrial flange and the ventricular portion. The annulus support includes a ring of anchors extending radially therefrom, with an annular clipping space defined between the atrial flange and the ring of anchors. A plurality of leaflet holders positioned at the atrial end of the atrial flange, and a plurality of valve leaflets secured to the leaflet holders, and positioned inside the atrial flange at a location above the native annulus.

Device and method for mitral valve regurgitation treatment

Growing community of inventors

Tianjin, China

Tianzhu Li